Mathew Maurer Receives Distinguished Clinical Research Achievement Award from Clinical Research Forum

2019 Top Ten Clinical Research Achievement Awardee

September 13, 2019

The Irving Institute congratulates Mathew S. Maurer, MD on receiving a 2019 Top Ten Clinical Research Achievement Award from the Clinical Research Forum. Dr. Maurer’s study, “Transthyretin Cardiac Amyloidosis: Overlooked, Under Appreciated and Treatable” received the additional honor of Distinguished Clinical Research Achievement Award, presented to the top two studies that show creativity, innovation, or a novel approach that demonstrates an immediate impact on the health and well-being of patients. Each study received a $5,000 cash prize.

Transthyretin amyloid cardiomyopathy is an under-diagnosed and often overlooked cause of heart failure. Dr. Maurer’s randomized, double blind, prospective, and international multicenter study evaluated the drug tafamidis for patients with the genetic and non-genetic forms of transthyretin amyloidosis. Use of the drug showed a significant reduction in mortality and frequency of cardiovascular-related hospitalizations. Collectively, these findings indicate that tafamidis is the first effective therapy for patients with transthyretin amyloid cardiomyopathy.

Read more about Dr. Maurer’s research story.


General Medicine, Campus News, Medicine, Cardiology